Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics

• Published in: Frontiers in immunology 2022-12, Vol.13, p.955476-955476
• Main Authors: Pal, Soumik, Sharma, Amit, Mathew, Sam Padalumavunkal, Jaganathan, Bithiah Grace
• Format: Article
• Language: English
• Subjects: cancer; cancer metabolism; cancer microenvironment; Carbohydrate Metabolism; Cell Transformation, Neoplastic - metabolism; Child; Glycolysis; Humans; Immunology; Male; Metabolic Networks and Pathways; metabolic reprogramming; Prostatic Neoplasms; targeted therapy
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.955476

Cancer is a heterogeneous disease characterized by various genetic and phenotypic aberrations. Cancer cells undergo genetic modifications that promote their proliferation, survival, and dissemination as the disease progresses. The unabated proliferation of cancer cells incurs an enormous energy demand that is supplied by metabolic reprogramming. Cancer cells undergo metabolic alterations to provide for increased energy and metabolite requirement; these alterations also help drive the tumor progression. Dysregulation in glucose uptake and increased lactate production "aerobic glycolysis" were described more than 100 years ago, and since then, the metabolic signature of various cancers has been extensively studied. However, the extensive research in this field has failed to translate into significant therapeutic intervention, except for treating childhood-ALL with amino acid metabolism inhibitor L-asparaginase. Despite the growing understanding of novel metabolic alterations in tumors, the therapeutic targeting of these tumor-specific dysregulations has largely been ineffective in clinical trials. This chapter discusses the major pathways involved in the metabolism of glucose, amino acids, and lipids and highlights the inter-twined nature of metabolic aberrations that promote tumorigenesis in different types of cancer. Finally, we summarise the therapeutic interventions which can be used as a combinational therapy to target metabolic dysregulations that are unique or common in blood, breast, colorectal, lung, and prostate cancer.